Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
BioRestorative Therapies (Nasdaq:BRTX) presented new preclinical data at ISCT 2026 on source-specific exosome and extracellular vesicle (EV) functionality from multiple mesenchymal stem cell (MSC) sources.
The work links distinct proteomic profiles to regenerative and aesthetic use cases, informing BioRestorative’s biology-driven BioCosmeceutical product design across dermatology and regenerative aesthetics.
BioRestorative Therapies (Nasdaq:BRTX) reported expanded blinded Phase 2 data for BRTX-100 showing sustained pain and functional improvements in chronic lumbar disc disease through 52 and 104 weeks. At 52 weeks, 52% of evaluable patients achieved ≥50% improvement in both VAS pain and ODI function (n=25). Multiple measures (VAS, ODI, RMDQ, FRI) showed sustained mean improvements; no dose-limiting toxicities were observed. BRTX-100 has FDA Fast Track designation and BioRestorative says it aligned with FDA on Phase 3 plans, initiating Phase 3 enabling activities with a goal to submit a Phase 3 IND later in 2026.
BioRestorative Therapies (Nasdaq: BRTX) will present new clinical and preclinical data at ISCT 2026 in Dublin, May 6-9. Presentations on May 6 include Phase 2 safety and blinded efficacy data for intradiscal MSC injections in chronic lumbar disc disease and preclinical exosome proteomics from its BioCosmeceutical platform.
The company will present at 9:15 AM and 7:00 PM on May 6, 2026, covering ongoing Phase 2 results and MSC exosome source-specific proteomics.
BioRestorative Therapies (NASDAQ:BRTX) announced a strategic partnership with Dr. David J. Goldberg to lead a prospective, controlled human clinical study of its regenerative BioCosmeceutical secretome-derived biologics produced in the company's cGMP, ISO-7 cleanroom.
The collaboration aims for publication-quality evidence, KOL-driven physician network access, multi-channel adoption across professional clinics, biologic dermal retail, medspas, and direct-to-consumer channels, plus conference dissemination beginning 2027 to support commercial positioning and adoption.
BioRestorative Therapies (Nasdaq:BRTX) announced a strategic collaboration with 203 Creates to build and commercialize a biocosmeceutical platform and launch the BioX™ consumer product portfolio.
The agreement covers brand architecture, digital infrastructure, omnichannel go-to-market execution, physician and DTC channels, private-label opportunities, and scalable manufacturing to accelerate time to market and global rollout.
BioRestorative Therapies (Nasdaq:BRTX) reported blinded Phase 2 data for BRTX-100 in chronic lumbar disc disease showing meaningful, sustained pain and function improvements and no dose-limiting toxicity-related adverse events.
Key endpoints: >30% improvement required for success; many patients achieved >50% improvement on VAS, ODI, RMDQ and FRI at 26, 52 and 104 weeks. FDA Type B meeting aligned on Phase 3 design and CMC approach.
BioRestorative Therapies (Nasdaq: BRTX) will present new blinded Phase 2 data for BRTX-100 on March 28, 2026, at the Orthopaedic Research Society meeting.
The update covers approximately 45 patients, reports meaningful improvements in pain and function scales, and confirms safety and tolerability. A pre-market press release will detail the results. Following a Type B meeting with FDA, the company said regulators raised no safety concerns and aligned on Phase 3 design elements, subject to final IND review.
BioRestorative Therapies (NASDAQ:BRTX) will attend the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026, to pursue commercialization of its BioCosmeceutical platform.
Commercial leadership, led by Crystal Romano, will meet potential partners, distributors, and practitioners to expand awareness, distribution, and adoption of regenerative skincare products using biologically active secretome components.
BioRestorative Therapies (NASDAQ:BRTX) reported several near‑term and strategic advances: completed enrollment of 99 patients in its randomized, sham‑controlled Phase 2 BRTX‑100 trial, received a positive FDA Type B meeting aligning on Phase 3 and CMC, initiated Phase 3 enabling activities, and raised $5.0 million in a public offering to strengthen its balance sheet.
The company is also expanding a BioCosmeceutical commercial platform and advancing ThermoStem® IP while targeting a Phase 3 IND amendment in H2 2026 and Phase 2 topline results in early 2027.
BioRestorative (NASDAQ:BRTX) announced that IP Australia allowed Patent Application No. 2020265664 on Feb. 24, 2026, covering non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates and methods of making them.
The allowance extends ThermoStem®'s Australian IP protection, focuses on an allogeneic, off-the-shelf BADSC platform for obesity and metabolic disorders, and signals continued global patent portfolio building for next-generation, cell-based alternatives to GLP-1 drugs.